270 related articles for article (PubMed ID: 24828490)
1. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
David M; Sahay D; Mege F; Descotes F; Leblanc R; Ribeiro J; Clézardin P; Peyruchaud O
PLoS One; 2014; 9(5):e97771. PubMed ID: 24828490
[TBL] [Abstract][Full Text] [Related]
2. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells.
Chen M; Towers LN; O'Connor KL
Am J Physiol Cell Physiol; 2007 May; 292(5):C1927-33. PubMed ID: 17496233
[TBL] [Abstract][Full Text] [Related]
3. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
[TBL] [Abstract][Full Text] [Related]
4. Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade.
Miyabe Y; Miyabe C; Iwai Y; Yokoyama W; Sekine C; Sugimoto K; Harigai M; Miyasaka M; Miyasaka N; Nanki T
Arthritis Res Ther; 2014 Oct; 16(5):461. PubMed ID: 25273676
[TBL] [Abstract][Full Text] [Related]
5. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis.
David M; Ribeiro J; Descotes F; Serre CM; Barbier M; Murone M; Clézardin P; Peyruchaud O
Int J Oncol; 2012 Apr; 40(4):1133-41. PubMed ID: 22200658
[TBL] [Abstract][Full Text] [Related]
6. Positive and Negative Cross-Talk between Lysophosphatidic Acid Receptor 1, Free Fatty Acid Receptor 4, and Epidermal Growth Factor Receptor in Human Prostate Cancer Cells.
Hopkins MM; Liu Z; Meier KE
J Pharmacol Exp Ther; 2016 Oct; 359(1):124-33. PubMed ID: 27474750
[TBL] [Abstract][Full Text] [Related]
7. Signal transduction responses to lysophosphatidic acid and sphingosine 1-phosphate in human prostate cancer cells.
Gibbs TC; Rubio MV; Zhang Z; Xie Y; Kipp KR; Meier KE
Prostate; 2009 Oct; 69(14):1493-506. PubMed ID: 19536794
[TBL] [Abstract][Full Text] [Related]
8. The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer.
Sahay D; Leblanc R; Grunewald TG; Ambatipudi S; Ribeiro J; Clézardin P; Peyruchaud O
Oncotarget; 2015 Aug; 6(24):20604-20. PubMed ID: 26098771
[TBL] [Abstract][Full Text] [Related]
9. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
Komachi M; Tomura H; Malchinkhuu E; Tobo M; Mogi C; Yamada T; Kimura T; Kuwabara A; Ohta H; Im DS; Kurose H; Takeyoshi I; Sato K; Okajima F
Carcinogenesis; 2009 Mar; 30(3):457-65. PubMed ID: 19129242
[TBL] [Abstract][Full Text] [Related]
10. LPA receptor1 antagonists as anticancer agents suppress human lung tumours.
Zhao PF; Wu S; Li Y; Bao G; Pei JY; Wang YW; Ma Q; Sun HJ; Damirin A
Eur J Pharmacol; 2020 Feb; 868():172886. PubMed ID: 31866407
[TBL] [Abstract][Full Text] [Related]
11. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
Li HY; Oh YS; Choi JW; Jung JY; Jun HS
Kidney Int; 2017 Jun; 91(6):1362-1373. PubMed ID: 28111010
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.
Yamada T; Sato K; Komachi M; Malchinkhuu E; Tobo M; Kimura T; Kuwabara A; Yanagita Y; Ikeya T; Tanahashi Y; Ogawa T; Ohwada S; Morishita Y; Ohta H; Im DS; Tamoto K; Tomura H; Okajima F
J Biol Chem; 2004 Feb; 279(8):6595-605. PubMed ID: 14660630
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites.
Sako A; Kitayama J; Shida D; Suzuki R; Sakai T; Ohta H; Nagawa H
J Surg Res; 2006 Jan; 130(1):94-101. PubMed ID: 16171822
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid regulates murine blastocyst development by transactivation of receptors for heparin-binding EGF-like growth factor.
Liu Z; Armant DR
Exp Cell Res; 2004 Jun; 296(2):317-26. PubMed ID: 15149861
[TBL] [Abstract][Full Text] [Related]
15. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid (LPA) as a modulator of plasma membrane Ca
Sant'Anna JF; Baldez VS; Razuck-Garrão NA; Lemos T; Diaz BL; Einicker-Lamas M
J Physiol Biochem; 2021 May; 77(2):321-329. PubMed ID: 33704695
[TBL] [Abstract][Full Text] [Related]
17. Antidepressants activate the lysophosphatidic acid receptor LPA(1) to induce insulin-like growth factor-I receptor transactivation, stimulation of ERK1/2 signaling and cell proliferation in CHO-K1 fibroblasts.
Olianas MC; Dedoni S; Onali P
Biochem Pharmacol; 2015 Jun; 95(4):311-23. PubMed ID: 25888927
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid receptor
Hoshino Y; Okuno T; Saigusa D; Kano K; Yamamoto S; Shindou H; Aoki J; Uchida K; Yokomizo T; Ito N
FASEB J; 2022 Apr; 36(4):e22236. PubMed ID: 35218596
[TBL] [Abstract][Full Text] [Related]
19. Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.
David M; Machuca-Gayet I; Kikuta J; Ottewell P; Mima F; Leblanc R; Bonnelye E; Ribeiro J; Holen I; Vales RL; Jurdic P; Chun J; Clézardin P; Ishii M; Peyruchaud O
J Biol Chem; 2014 Mar; 289(10):6551-6564. PubMed ID: 24429286
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidic acid stimulates prostaglandin E2 production in cultured stromal endometrial cells through LPA1 receptor.
Woclawek-Potocka I; Kondraciuk K; Skarzynski DJ
Exp Biol Med (Maywood); 2009 Aug; 234(8):986-93. PubMed ID: 19491366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
